Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0303
Sponsor: Hokkaido Gastrointestinal Cancer Study Group
This PHASE2 trial investigates Gastric Cancer and is currently suspended. Hokkaido Gastrointestinal Cancer Study Group leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Suspended PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Suspended PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Suspended PHASE2
First recorded
Jan 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hokkaido Gastrointestinal Cancer Study Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Sapporo, Japan